To date, Bintrafusp alfa (BA), a fusion protein that can simultaneously inhibit both TGF-β and PD-L1 pathway, was demonstrated to possess a stronger affinity with TGF-β1 and inhibition of cancer cell proliferation than Fresolimumab in MC38 tumors [237, 238]. Here, TGFB1 is linked to cancer.